Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 7/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TRHR | P34981 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10359347 | 0.90 | TRHR (0.42) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL19359174 | 0.90 | TRHR (0.42) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL28864215 | 0.90 | TRHR (0.42) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL19875638 | 0.89 | ALDH1A1 (0.45) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL9719683 | 0.89 | ALDH1A1 (0.45) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL9719680 | 0.89 | ALDH1A1 (0.45) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL31199181 | 0.84 | NTSR2 (0.44) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL11175840 | 0.83 | TSHR (0.47) | HDAC3HDAC11HDAC6HDAC1HDAC10 | |
| SCHEMBL10335427 | 0.82 | HDAC3 (0.39) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL11162675 | 0.82 | TSHR (0.48) | HDAC3HDAC11HDAC6HDAC1HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | HDAC3 3886/4885HDAC11 3297/4885HDAC6 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.